Ben J L Van den Branden Selected Research

Stents

3/2015	Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions.
11/2013	Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions.
6/2013	Late catch-up in lumen diameter at five-year angiography in MACE-free patients treated with sirolimus-eluting stents in the Primary Stenting of Totally Occluded Native Coronary Arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II).
12/2012	A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study.
2/2012	Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II study).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ben J L Van den Branden Research Topics

Disease

5	Coronary Occlusion 03/2015 - 02/2012
3	Thrombosis (Thrombus) 03/2015 - 02/2012
1	Aortic Valve Stenosis (Aortic Stenosis) 01/2022
1	Tricuspid Valve Insufficiency (Insufficiency, Tricuspid Valve) 12/2017
1	Coronary Artery Disease (Coronary Atherosclerosis) 12/2017
1	Neointima 12/2012
1	Cardiovascular Diseases (Cardiovascular Disease) 12/2012
1	Pathologic Constriction (Stenosis) 12/2012
1	Mitral Valve Insufficiency (Mitral Regurgitation) 01/2012

Drug/Important Bio-Agent (IBA)

5	Sirolimus (Rapamycin)FDA Link 03/2015 - 02/2012
2	zotarolimusIBA 03/2015 - 11/2013
2	MetalsIBA 06/2013 - 02/2012
1	SDMIBA 01/2022
1	Brain Natriuretic Peptide (Natrecor)FDA Link 12/2017
1	omega-Chloroacetophenone (Mace)IBA 06/2013
1	Everolimus FDA Link 12/2012
1	Phenobarbital (Luminal)FDA Link 12/2012
1	PolymersIBA 12/2012

Therapy/Procedure

5	Stents 03/2015 - 02/2012
1	Drug-Eluting Stents 12/2012
1	Surgical Instruments (Clip) 01/2012